secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeMD, Inc. (LFMD)
CIK:        0000948320
Form:       8-K
Filed at:   2026-06-22T12:25:56+00:00
Accession:  0001493152-26-029503
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeMD partners with Halozyme for exclusive telehealth co-marketing of XYOSTED, launching July 2026 in 37 states
--------------------------------------------------------------------------------

- LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.
- Program launches July 2026; initially available in 37 states with a transparent $249/month all-inclusive price.
- LifeMD's affiliated medical group will evaluate patients, and its pharmacy will be the preferred dispensing pharmacy.
- Three-year initial term with automatic renewal; either party can terminate if co-marketing budget missed for two consecutive quarters.
- Companies will jointly invest in consumer education and promotional initiatives to expand awareness of hypogonadism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/948320/000149315226029503/0001493152-26-029503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/948320/000149315226029503/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-029503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer